Hugel is a global biopharmaceutical company, specializing in the aesthetic market with its proprietary botulinum toxin formulation. Based on its own success history of evolving from a venture to a global company, Hugel has been incubating innovative ventures as a venture accelerator. Since the beginning of ImmunoForge, Hugel has been its financial and strategic accelerator.
PhaseBio Pharmaceuticals is a Nasdaq-registered company focusing on the development and commercialization of novel therapies for orphan diseases. ImmunoForge has licensed in the global rights of a long-acting, recombinant GLP-1 analogue (PF1801) from PhaseBio. ImmunoForge, based on its new use invention of GLP-1, is repositioning PF1801 for various indications.